Impact of Empagliflozin on Cardiac Arrhythmias and Heart Rate Variability in Kidney Transplant Recipients
Transplantation Proceedings · 2025
DOI: 10.1016/j.transproceed.2025.02.045 ↗Kurz gefasst
Fachartikel in der Zeitschrift Transplantation Proceedings, 2025. Verfasst von Kenan Evren Öztop und 12 weiteren Autor:innen. Beteiligte Einrichtung: Division of Nephrology, Sakarya University Faculty of Medicine, Sakarya, Turkey. Electronic address: koztop@sakarya.edu.tr. Hauptthemen laut MEDLINE: Benzhydryl Compounds, Heart Rate, Kidney Transplantation, Glucosides. Die Arbeit wurde bisher 1-mal zitiert (Crossref) und nennt 17 Literaturangaben.
Abstract (Originalsprache)
AIM: We aimed to investigate the effects of Empagliflozin on cardiac arrhythmias and heart rate variability in kidney transplant recipients (KTRs). METHODS: Twenty-seven diabetic patients who underwent kidney transplantation between August 2020 and August 2023 were included. Patients with HbA1c >8% were received Empagliflozin treatment. A 24-hour Holter ECG monitoring was performed before and one year after beginning Empagliflozin. Holter ECGs were evaluated by a single cardiologist, comparing ventricular ectopic beats (VEB) and supraventricular ectopic beats (SEB) arrhythmias and heart rate variability parameters before and after one year of Empagliflozin treatment. RESULTS: Twenty-seven patients completed the study, and the mean patient age was 56.1 ± 10 years. Fifteen of the patients (55.6%) were male. The mean duration since transplant before starting Empagliflozin was 62.8 ± 46.2 months. In follow-up, HbA1c decreased from 8.2% to 7.7%(P = .075), urine protein/creatinine ratio reduced from 0.437 ± 0.428 to 0.267 ± 0.146 gr/g (P = .056), and platelet count increased significantly (P = .004). After one year of treatment, the number of VEBs and SEBs in the patients decreased compared to pretreatment. They decreased from 173.5 ± 460.8 and 514.8 ± 265 beats before treatment to 125.1 ± 231.7 and 125.1 ± 231.7 beats after treatment, respectively, but did not reach statistical significance (P > .05). No significant changes were found in heart rate variability parameters (P > .05). No significant correlation was found between VEBs and SEBs and cardiac inflammation indicators (P > .05). CONCLUSION: This study, for the first time, investigated the effect of Empagliflozin on cardiac arrhythmias and heart rate variability in diabetic KTRs. Empagliflozin did not significantly affect cardiac arrhythmias and heart rate variability in KTRs.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Substanzen
Autor:innen und Institutionen
- Division of Nephrology, Sakarya University Faculty of Medicine, Sakarya, Turkey. Electronic address: koztop@sakarya.edu.tr.
- Department of Cardiology, Sakarya University Faculty of Medicine, Sakarya, Turkey.
- Division of Nephrology, Sakarya University Faculty of Medicine, Sakarya, Turkey.
- Division of Endocrinology, Sakarya University Faculty of Medicine, Sakarya, Turkey.
- Department of Pathology, Sakarya University Faculty of Medicine, Sakarya, Turkey.
- Department of General Surgery, Sakarya University Faculty of Medicine, Sakarya, Turkey.
Zitieren
APA
Öztop, K. E., Can, Y., İslam, M., Demirci, T., Çakar, G. C., Fırat, N., Pınar, M., Ercan, Z., Akın, E., Salihi, S., Genç, A. C., Altıntoprak, F., & Dheir, H. (2025). Impact of Empagliflozin on Cardiac Arrhythmias and Heart Rate Variability in Kidney Transplant Recipients. Transplantation Proceedings. https://doi.org/10.1016/j.transproceed.2025.02.045
Vancouver
Öztop KE, Can Y, İslam M, Demirci T, Çakar GC, Fırat N, et al. Impact of Empagliflozin on Cardiac Arrhythmias and Heart Rate Variability in Kidney Transplant Recipients. Transplantation Proceedings. 2025. doi:10.1016/j.transproceed.2025.02.045
BibTeX
@article{ztop2025,
author = {Öztop, Kenan Evren and Can, Yusuf and İslam, Mahmud and Demirci, Taner and Çakar, Gözde Cakırsoy and Fırat, Necattin and Pınar, Musa and Ercan, Zafer and Akın, Emrah and Salihi, Salih and Genç, Ahmed Cihad and Altıntoprak, Fatih and Dheir, Hamad},
title = {Impact of Empagliflozin on Cardiac Arrhythmias and Heart Rate Variability in Kidney Transplant Recipients},
journal = {Transplantation Proceedings},
year = {2025},
doi = {10.1016/j.transproceed.2025.02.045}
}
EUVIMED